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Original Paper 
Breast cancer is developed from the breast tumors. 
There are more than 18 sub-types of this cancer. 
This type of  cancer is the second cause of mortality 
in women (1,2). The etiology of breast cancer is 
multi factorial. Genetic factors are interfered in the 
etiology of breast cancer. The FAS gene, has a 
critical role in the tumor growth and metastasis (2). 
Two polymorphisms have been identified in the FAS 
promoter region one in the silencer region, G to A 
substitution at nucleotide  position −670 (rs1800682) 
(3).  
Breast cancer is the second cause of mortality in women. The etiology of 
breast cancer is multi factorial. Genetic factors play an important role in the 
etimology of breast cancer. The FAS gene, has a critical role in the tumor 
growth and metastasis. Gene polymorphisms including -1377 G>A  and -670 
A/G in FAS gene have shown to change the transcription activities of this 
gene. The FAS genotypes were determined by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) in 115 breast cancer 
patients, 115 healthy controls, all female and selected from city of Mashhad 
in north-eastern part of Iran. BstuI and ScrfI were used  as endonuclease 
enzymes to detect -1377G/A and  -670A/G gene polymorphisms, 
respectively. GG, GA and AA genotype frequencies for FAS -1377 
polymorphism in patients  were   30.4%, 49.6% and 20%, whereas in healthy 
controls were 26.1%, 50.4% and 23.5%, respectively and there was no 
significant difference between case and controls (p=0.7).Additionally, 
genotype frequencies of FAS -670 AA, AG and GG in patient groups were 
52.2%, 39.1% and 8.7% respectively . The result of genotype frequency in 
controls for FAS -670 AA, AG and GG was 47%, 41% and 10.4%, which 
Showed insignificant difference as compared with patients genotypes 
(p=0.78). These results showed that FAS−1377G/A and FAS -670 A/G gene 
polymorphisms had a strong linkage disequilibrium with  p value <0.001. 
These results indicated the lack of association between FAS−1377G>A and 
FAS -670 A/G gene polymorphisms and risk of breast cancer. Moreover, a 
significant linkage disequilibrium was found betweenFAS−1377G/A and 
FAS -670 A/G gene polymorphisms in case and control groups.  
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These polymorphisms have shown to change the 
transcription activities of  FAS gene[4].In the 
present study, We aimed to determine the linkage 
disequilibrium between -670 A>G and -1377 G>A 
polymorphisms in FAS gene in patients with breast 
cancer and controls. 
 
Materials and Methods 
  We carried out a case-control genetic study in a 
population selected from Omid Cancer Hospital of 
Mashhad in north - eastern part of Iran during the 
period from February 2013 - October 2014. This 
study involved a group of 115  female patients with 
histologically-confirmed diagnosis of Breast cancer 
and 115 healthy controls with negative medical 
history. DNA was extracted by DNA extraction  kit.  
These target sequences were amplified according to 
the recipe in Table1. PCR amplifications were 
conducted in Personal Cycler™ amplificator 
(Biometra, Germany). Thermal cycling conditions 
were as follows Table 2. 
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FAS – 670A/G 
lμVolume –
based 
  
FAS -1377 
G/A 
lμVolume –
based 
  
1 1 Genomic DNA(100ng) 
0.4 0.4 dNTP(0.2µm) 
2 2 PCR buffer(10x) 
0.6 0.6 MgCl2  (25µm) 
0.8 0.8 Reverse Primer( 10pmol) 
0.8 0.8 Forward Primer( 10pmol) 
1 1 Taq DNA polymerase(5 U/µL) 
13.4 13.4 Deionised H2O 
20 20 Total 
Table1. Reaction  setup  
  
1377- 670- 
Temperature 
˚C Time 
Tempera-
ture ˚C Time 
Initial denatura-
tion for1cycle 94 2 min 94 2 min 
Denaturation 94 30 s 94 30 s 
Annealing 69 30 s 62 30 s 
Extension 72 45 s 72 45 s 
Go to step 2 
for35cycles   
final extension 72 min 7 72 min 7 
Table2. Thermocycling conditions for PCR 
Spectrophotometry  and  1 %  agarose  gel 
electrophoresis methods were used to determine 
quality of the extracted DNA.   
  
The primer sequences were as follows:  
 
FAS  -1377 G/A 
F  5´-TGTGTGCACAAGGCTGGCGC -3'   
R  5´-TGCATCTGTCACTGCACTTACCACCA- 3 
FAS -670 A/G 
F    5´- ATAGCTGGGGCTATGCGATT-3' 
R     5´-CATTTGACTGGGCTGTCCAT-3' 
4 μL of PCR products were digested overnight at 
37°C in a 10 μL reaction volume containing 1 units 
of BstuI and ScrfI (Fermentas, Germany) were 
recruited as endonuclease enzymes to detect -
1377G/A and  -670A/G gene polymorphisms, 
respectively. After overnight , the digestion 
solutions were analyzed on 17% acrylamide gel and 
then visualized with silver-nitrate staining. (Figure 
1),(Figure 2). 
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 Restriction digestion analysis of PCR products 
with and on 17% acrylamide gel. 
(Fig.1) FAS-1377G/A  Lane1: AA homozygote 
with 122 bp ; Lane 2,3: GG homozygote with 104bp; 
Lane4,5: GA heterozygote  genotype with 122bp and 
104bp .Size marker of DNA (50bp ladder). 
 (Fig.2) FAS-670 A/G Lane1: AG heterozygote  
genotype with 193bp and 136bp, Lane 2: 136 bp GG 
homozygote  and lane3,4:193bp AA homozygote  
respectively; Size marker of DNA (100bp ladder).  
Statistical analysis 
  The statistical analysis of the data was performed 
by using the SPSS 18.0 software. Genotypes and 
alleles were compared between groups by use of χ2 
test. The strength of the association between the 
polymorphisms and cancer risk was measured by 
odds ratios (ORs) with 95% confidence intervals
(CIs). The allele frequencies of 2 polymorphisms in 
case and control groups followed Hardy-Weinberg‘s 
law of Equilibrium (P > 0.05) .  
 
Results 
  The frequencies of the two alleles in breast cancer  
patients were compared with the frequencies in the 
healthy control subjects. In the same order , GG, GA 
and AA genotype frequencies for FAS -1377 
polymorphism in patients were 30.4%, 49.6% and 
20%, whereas in control groups were 26.1%, 50.4% 
and 23.5%, and there was no significant difference 
between case and control groups. Furthermore, 
genotype frequencies of FAS -670 AA, AG and GG 
in patients were 52.2%, 39.1% and 8.7% 
respectively. The result of genotype frequencies in 
control groups for FAS -670 AA, AG and GG were 
47%, 41% and 10.4%, which Showed insignificant 
difference as compared with patients 
genotypes .These results showed that FAS−1377G/A 
and FAS -670 A/G gene polymorphisms had a 
strong linkage disequilibrium with ( p value <0.001). 
 
Discussion 
   Several polymorphism sites have been identified 
to influence the development of breast cancer (2,7). 
Death receptor activation triggers extrinsic apoptotic 
pathways, which in some cell types may be  enough 
to carry apoptosis (11-13). 
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Several previous researches concentrated on the 
association between different gene polymorphisms 
within cell death pathways and the risk of 
developing malignancies and developing cancers. 
FAS polymorphisms may play different, context-
dependent roles in cancer (14,15) Crew et al., found 
no association between breast cancer and FAS -1377 
G/A, FAS-670 G/A polymorphisms (16). On the 
other hand, Zhang et al., reported an important 
association between FAS 1377G/A gene 
polymorphism and risk of breast cancer, but they 
reported no association between FAS -670 G/A and 
breast cancer risk (17). 
Hashemi et al., mentioned that the FAS-1377 G/A 
did not affect the risk of breast cancer, while FAS -
670 G/A gene polymorphism was risk factor[4]. 
Krippl et al., in a study of 500 breast cancer patients 
and 500 controls in a Caucasian population in 
Austria, found a significant association between 
FAS-1377G/A and increased risk of breast cancer, 
but they reported no associations with FAS -670G/ 
A (18). 
Our study  indicates the lack of association between 
FAS−1377G>A and FAS -670 A/G gene 
polymorphisms and risk of breast cancer. Also, a 
main linkage disequilibrium is found 
betweenFAS−1377G/A and FAS -670 A/G gene 
polymorphisms in case and control groups. 
One of the limitation in our study is small sample 
size.  
www.thecancerpress.com 
Conclusions 
While there have been current discussions on the influence of various polymorphisms within the signaling 
molecules relevant to cell death pathways, and cancer formation , this work has proved its worth. Also , 
we suggest to study the other candidate gene polymorphism which may be beneficial for identifying the 
factors involved in breast cancer. 
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